Vaxart (VXRT) — Fundamentals Overview

By Emilio Sanchez • Thursday, September 07 12:06 • Permanent Link

Vaxart sank -7.0% today, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Vaxart has moved -74.0% over the last year, and the S&P 500 logged a change of 12.0%
VXRT has an average analyst rating of buy and is -83.47% away from its mean target price of $4.5 per share
Its trailing earnings per share (EPS) is $-0.77
Vaxart has a trailing 12 month Price to Earnings (P/E) ratio of -1.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-0.59 and its forward P/E ratio is -1.3
The company has a Price to Book (P/B) ratio of 1.33 in contrast to the S&P 500's average ratio of 2.95
Vaxart is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-51300376, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.